Link Pharma Chem（524748）株式概要リンク・ファーマ・ケム・リミテッドは、インドで製薬、農業、特殊化学品産業向けの有機中間体の製造・販売を行っている。 詳細524748 ファンダメンタル分析スノーフレーク・スコア評価0/6将来の成長0/6過去の実績1/6財務の健全性2/6配当金0/6報酬今年は黒字化を達成 リスク分析過去5年間で収益は年間51%減少しました。 利払いは収益で十分にカバーされない Indian市場と比較して、過去 3 か月間の株価の変動が非常に大きい意味のある時価総額がありません ( ₹133M )+2 さらなるリスクすべてのリスクチェックを見る524748 Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair Value₹Current Price₹29.88330.5% 割高 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-18m535m2016201920222025202620282031Revenue ₹142.1mEarnings ₹704.7kAdvancedSet Fair ValueView all narrativesLink Pharma Chem Limited 競合他社Kuwer IndustriesSymbol: BSE:530421Market cap: ₹122.5mRite Zone Chemcon IndiaSymbol: NSEI:RITEZONEMarket cap: ₹88.4mL.K. Mehta PolymersSymbol: BSE:544366Market cap: ₹162.6mVinyoflexSymbol: BSE:530401Market cap: ₹224.6m価格と性能株価の高値、安値、推移の概要Link Pharma Chem過去の株価現在の株価₹29.8852週高値₹42.8052週安値₹21.00ベータ0.581ヶ月の変化0.27%3ヶ月変化2.93%1年変化-15.28%3年間の変化-27.65%5年間の変化-10.14%IPOからの変化509.80%最新ニュースお知らせ • May 14Link Pharma Chem Limited to Report Q4, 2026 Results on May 21, 2026Link Pharma Chem Limited announced that they will report Q4, 2026 results on May 21, 2026Valuation Update With 7 Day Price Move • Mar 16Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to ₹23.40, the stock trades at a trailing P/E ratio of 76.8x. Average trailing P/E is 21x in the Chemicals industry in India. Total loss to shareholders of 39% over the past three years.Recent Insider Transactions • Mar 15Whole-Time Chairman recently bought ₹1.0m worth of stockOn the 13th of March, Satish Thakur bought around 41k shares on-market at roughly ₹25.21 per share. This transaction amounted to 4.3% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was Satish's only on-market trade for the last 12 months.Reported Earnings • Feb 16Third quarter 2026 earnings released: EPS: ₹0.15 (vs ₹1.50 loss in 3Q 2025)Third quarter 2026 results: EPS: ₹0.15 (up from ₹1.50 loss in 3Q 2025). Revenue: ₹65.3m (up 22% from 3Q 2025). Net income: ₹682.0k (up ₹7.35m from 3Q 2025). Profit margin: 1.0% (up from net loss in 3Q 2025). Over the last 3 years on average, earnings per share has fallen by 25% per year but the company’s share price has only fallen by 13% per year, which means it has not declined as severely as earnings.お知らせ • Feb 07Link Pharma Chem Limited to Report Q3, 2026 Results on Feb 14, 2026Link Pharma Chem Limited announced that they will report Q3, 2026 results at 9:15 AM, Indian Standard Time on Feb 14, 2026New Risk • Jan 28New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Indian stocks, typically moving 8.7% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (15% operating cash flow to total debt). Share price has been highly volatile over the past 3 months (8.7% average weekly change). Earnings have declined by 52% per year over the past 5 years. Market cap is less than US$10m (₹126.3m market cap, or US$1.37m). Minor Risk Revenue is less than US$5m (₹259m revenue, or US$2.8m).最新情報をもっと見るRecent updatesお知らせ • May 14Link Pharma Chem Limited to Report Q4, 2026 Results on May 21, 2026Link Pharma Chem Limited announced that they will report Q4, 2026 results on May 21, 2026Valuation Update With 7 Day Price Move • Mar 16Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to ₹23.40, the stock trades at a trailing P/E ratio of 76.8x. Average trailing P/E is 21x in the Chemicals industry in India. Total loss to shareholders of 39% over the past three years.Recent Insider Transactions • Mar 15Whole-Time Chairman recently bought ₹1.0m worth of stockOn the 13th of March, Satish Thakur bought around 41k shares on-market at roughly ₹25.21 per share. This transaction amounted to 4.3% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was Satish's only on-market trade for the last 12 months.Reported Earnings • Feb 16Third quarter 2026 earnings released: EPS: ₹0.15 (vs ₹1.50 loss in 3Q 2025)Third quarter 2026 results: EPS: ₹0.15 (up from ₹1.50 loss in 3Q 2025). Revenue: ₹65.3m (up 22% from 3Q 2025). Net income: ₹682.0k (up ₹7.35m from 3Q 2025). Profit margin: 1.0% (up from net loss in 3Q 2025). Over the last 3 years on average, earnings per share has fallen by 25% per year but the company’s share price has only fallen by 13% per year, which means it has not declined as severely as earnings.お知らせ • Feb 07Link Pharma Chem Limited to Report Q3, 2026 Results on Feb 14, 2026Link Pharma Chem Limited announced that they will report Q3, 2026 results at 9:15 AM, Indian Standard Time on Feb 14, 2026New Risk • Jan 28New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Indian stocks, typically moving 8.7% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (15% operating cash flow to total debt). Share price has been highly volatile over the past 3 months (8.7% average weekly change). Earnings have declined by 52% per year over the past 5 years. Market cap is less than US$10m (₹126.3m market cap, or US$1.37m). Minor Risk Revenue is less than US$5m (₹259m revenue, or US$2.8m).Reported Earnings • Nov 15Second quarter 2026 earnings released: EPS: ₹0.03 (vs ₹0.69 loss in 2Q 2025)Second quarter 2026 results: EPS: ₹0.03 (up from ₹0.69 loss in 2Q 2025). Revenue: ₹63.4m (up 32% from 2Q 2025). Net income: ₹156.0k (up ₹3.22m from 2Q 2025). Profit margin: 0.2% (up from net loss in 2Q 2025). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 61% per year but the company’s share price has only fallen by 5% per year, which means it has not declined as severely as earnings.お知らせ • Nov 08Link Pharma Chem Limited to Report Q2, 2026 Results on Nov 13, 2025Link Pharma Chem Limited announced that they will report Q2, 2026 results on Nov 13, 2025New Risk • Oct 07New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Indian stocks, typically moving 8.3% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (8.3% average weekly change). Earnings have declined by 50% per year over the past 5 years. Market cap is less than US$10m (₹154.3m market cap, or US$1.74m). Minor Risks High level of debt (45% net debt to equity). Revenue is less than US$5m (₹244m revenue, or US$2.7m).お知らせ • Aug 13Link Pharma Chem Limited, Annual General Meeting, Sep 09, 2025Link Pharma Chem Limited, Annual General Meeting, Sep 09, 2025, at 11:30 Indian Standard Time.Reported Earnings • Aug 02First quarter 2026 earnings released: EPS: ₹0.91 (vs ₹0.67 in 1Q 2025)First quarter 2026 results: EPS: ₹0.91 (up from ₹0.67 in 1Q 2025). Revenue: ₹80.2m (down 9.3% from 1Q 2025). Net income: ₹4.02m (up 36% from 1Q 2025). Profit margin: 5.0% (up from 3.4% in 1Q 2025). The increase in margin was driven by lower expenses. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 65 percentage points per year, which is a significant difference in performance.お知らせ • Jul 24Link Pharma Chem Limited to Report Q1, 2026 Results on Aug 01, 2025Link Pharma Chem Limited announced that they will report Q1, 2026 results on Aug 01, 2025New Risk • Jun 29New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 46% per year over the past 5 years. Market cap is less than US$10m (₹168.7m market cap, or US$1.97m). Minor Risks High level of debt (45% net debt to equity). Share price has been volatile over the past 3 months (7.6% average weekly change). Revenue is less than US$5m (₹254m revenue, or US$3.0m).Reported Earnings • May 28Full year 2025 earnings released: ₹2.31 loss per share (vs ₹3.07 loss in FY 2024)Full year 2025 results: ₹2.31 loss per share (improved from ₹3.07 loss in FY 2024). Revenue: ₹256.2m (down 14% from FY 2024). Net loss: ₹10.3m (loss narrowed 25% from FY 2024). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 76 percentage points per year, which is a significant difference in performance.お知らせ • May 19Link Pharma Chem Limited to Report Q4, 2025 Results on May 27, 2025Link Pharma Chem Limited announced that they will report Q4, 2025 results on May 27, 2025New Risk • Apr 29New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (0.4x net interest cover). Earnings have declined by 38% per year over the past 5 years. Market cap is less than US$10m (₹159.0m market cap, or US$1.87m). Minor Risks Share price has been volatile over the past 3 months (8.7% average weekly change). Revenue is less than US$5m (₹270m revenue, or US$3.2m).Reported Earnings • Feb 08Third quarter 2025 earnings released: ₹1.50 loss per share (vs ₹0.50 profit in 3Q 2024)Third quarter 2025 results: ₹1.50 loss per share (down from ₹0.50 profit in 3Q 2024). Revenue: ₹47.8m (down 40% from 3Q 2024). Net loss: ₹6.67m (down 402% from profit in 3Q 2024). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 78 percentage points per year, which is a significant difference in performance.お知らせ • Jan 28Link Pharma Chem Limited to Report Q3, 2025 Results on Feb 07, 2025Link Pharma Chem Limited announced that they will report Q3, 2025 results on Feb 07, 2025Reported Earnings • Nov 13Second quarter 2025 earnings released: ₹0.69 loss per share (vs ₹2.30 loss in 2Q 2024)Second quarter 2025 results: ₹0.69 loss per share (improved from ₹2.30 loss in 2Q 2024). Revenue: ₹51.6m (down 14% from 2Q 2024). Net loss: ₹3.06m (loss narrowed 70% from 2Q 2024). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 89 percentage points per year, which is a significant difference in performance.お知らせ • Oct 31Link Pharma Chem Limited to Report Q2, 2025 Results on Nov 11, 2024Link Pharma Chem Limited announced that they will report Q2, 2025 results on Nov 11, 2024お知らせ • Oct 06Link Pharma Chem Limited Announces Cessation of DirectorsLink Pharma Chem Limited informed that Mr. Suresh Balram Dhatrak (DIN: 00365256) and Mr. Devang Uttamchand Shah (DIN: 00704950), Independent directors have completed their tenure of 10 years i.e second term on 26th September, 2024 and consequently ceased to be an Independent Directors of the Company w.e.f. close of business hours on 26th September, 2024.お知らせ • Sep 05Link Pharma Chem Limited, Annual General Meeting, Sep 27, 2024Link Pharma Chem Limited, Annual General Meeting, Sep 27, 2024, at 11:30 Indian Standard Time.Reported Earnings • Aug 10First quarter 2025 earnings released: EPS: ₹0.67 (vs ₹1.85 loss in 1Q 2024)First quarter 2025 results: EPS: ₹0.67 (up from ₹1.85 loss in 1Q 2024). Revenue: ₹91.2m (up 16% from 1Q 2024). Net income: ₹2.96m (up ₹11.2m from 1Q 2024). Profit margin: 3.3% (up from net loss in 1Q 2024). The move to profitability was driven by higher revenue. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 97 percentage points per year, which is a significant difference in performance.お知らせ • Aug 02Link Pharma Chem Limited to Report Q1, 2025 Results on Aug 09, 2024Link Pharma Chem Limited announced that they will report Q1, 2025 results on Aug 09, 2024Reported Earnings • Jun 04Full year 2024 earnings released: ₹3.07 loss per share (vs ₹1.47 profit in FY 2023)Full year 2024 results: ₹3.07 loss per share (down from ₹1.47 profit in FY 2023). Revenue: ₹305.4m (down 21% from FY 2023). Net loss: ₹13.6m (down 308% from profit in FY 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 86 percentage points per year, which is a significant difference in performance.お知らせ • May 23Link Pharma Chem Limited to Report Q4, 2024 Results on May 29, 2024Link Pharma Chem Limited announced that they will report Q4, 2024 results on May 29, 2024Reported Earnings • Feb 11Third quarter 2024 earnings released: EPS: ₹0.50 (vs ₹0.40 in 3Q 2023)Third quarter 2024 results: EPS: ₹0.50 (up from ₹0.40 in 3Q 2023). Revenue: ₹83.1m (down 11% from 3Q 2023). Net income: ₹2.21m (up 23% from 3Q 2023). Profit margin: 2.7% (up from 1.9% in 3Q 2023). The increase in margin was driven by lower expenses. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 88 percentage points per year, which is a significant difference in performance.お知らせ • Feb 01Link Pharma Chem Limited to Report Q3, 2024 Results on Feb 09, 2024Link Pharma Chem Limited announced that they will report Q3, 2024 results on Feb 09, 2024Reported Earnings • Nov 10Second quarter 2024 earnings released: ₹2.30 loss per share (vs ₹2.16 profit in 2Q 2023)Second quarter 2024 results: ₹2.30 loss per share (down from ₹2.16 profit in 2Q 2023). Revenue: ₹60.2m (down 29% from 2Q 2023). Net loss: ₹10.2m (down 206% from profit in 2Q 2023). Over the last 3 years on average, earnings per share has fallen by 46% per year but the company’s share price has increased by 24% per year, which means it is well ahead of earnings.お知らせ • Nov 09Link Pharma Chem Limited Announces CFO ChangesLink Pharma Chem Limited informed that Mr. Sanjib Dutta has appointed as Chief Financial Officer (KMP) of the Company with effect from 08th November, 2023 at the meeting of Board of Directors held on 8th November, 2023. Mr. Sanjib Dutta is Commerce Graduate from Calcutta University, and having 27 Years of Work-Experience in Company Accounts, Banking, Goods and Services Tax, Commercial Part & Statutory Compliances etc.Board Change • Nov 07Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 2 highly experienced directors. Independent Director Rachna Ghai was the last director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.お知らせ • Nov 01Link Pharma Chem Limited Announces Resignation of Mr. Jayesh Pushpavadan Jani as Chief Financial OfficerLink Pharma Chem Limited announced that Mr. Jayesh Pushpavadan Jani has tendered his resignation from the post of Chief Financial Officer (KMP) of the Company with effect from 31st October, 2023 (closing business hours) due to almost attaining the age of retirement.お知らせ • Aug 29Link Pharma Chem Limited, Annual General Meeting, Sep 21, 2023Link Pharma Chem Limited, Annual General Meeting, Sep 21, 2023, at 11:30 Indian Standard Time. Agenda: To consider and adopt the Audited Financial Statements for the Financial Year ended March 31, 2023 and the Reports of the Board of Directors and Auditors thereon; to appoint a director in place of Mr. Rishikesh Thakur, who retires by rotation and, being eligible, offers himself for re-appointment; to consider appointment of Mr. Satish G. Thakur as a Chairman & Whole-time Director; and to consider other matters.お知らせ • Aug 06Link Pharma Chem Limited to Report Q1, 2024 Results on Aug 14, 2023Link Pharma Chem Limited announced that they will report Q1, 2024 results on Aug 14, 2023お知らせ • Jul 12Link Pharma Chem Limited Announces Disruption in Operation at Nandesari Plant of the Company Due to Closure Notice from Gujarat Pollution Control BoardLink Pharma Chem Limited has received notice from the Gujarat Pollution Control Board, Gandhinagar effecting closure of operations of its plant situated at Nandesari, Dist. Vadodara. Gujarat Pollution Control Board (GPCB) has laid certain conditions and has asked the Company to fulfil the same. The Company after analyzing order has started taking effective steps as directed by the GPCB to seek relief against the order.Reported Earnings • May 31Full year 2023 earnings released: EPS: ₹1.47 (vs ₹4.24 in FY 2022)Full year 2023 results: EPS: ₹1.47 (down from ₹4.24 in FY 2022). Revenue: ₹386.1m (down 28% from FY 2022). Net income: ₹6.54m (down 65% from FY 2022). Profit margin: 1.7% (down from 3.5% in FY 2022). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 4% per year but the company’s share price has increased by 33% per year, which means it is tracking significantly ahead of earnings growth.お知らせ • May 20Link Pharma Chem Limited to Report Q4, 2023 Results on May 29, 2023Link Pharma Chem Limited announced that they will report Q4, 2023 results on May 29, 2023Reported Earnings • Feb 12Third quarter 2023 earnings released: EPS: ₹0.40 (vs ₹1.58 in 3Q 2022)Third quarter 2023 results: EPS: ₹0.40 (down from ₹1.58 in 3Q 2022). Revenue: ₹93.6m (down 33% from 3Q 2022). Net income: ₹1.79m (down 75% from 3Q 2022). Profit margin: 1.9% (down from 5.0% in 3Q 2022). Over the last 3 years on average, earnings per share has increased by 24% per year but the company’s share price has increased by 46% per year, which means it is tracking significantly ahead of earnings growth.お知らせ • Feb 03Link Pharma Chem Limited to Report Q3, 2023 Results on Feb 09, 2023Link Pharma Chem Limited announced that they will report Q3, 2023 results on Feb 09, 2023Valuation Update With 7 Day Price Move • Jan 27Investor sentiment deteriorates as stock falls 20%After last week's 20% share price decline to ₹56.95, the stock trades at a trailing P/E ratio of 15.4x. Average trailing P/E is 19x in the Chemicals industry in India. Total returns to shareholders of 307% over the past three years.Valuation Update With 7 Day Price Move • Jan 10Investor sentiment improved over the past weekAfter last week's 18% share price gain to ₹67.20, the stock trades at a trailing P/E ratio of 18.1x. Average trailing P/E is 19x in the Chemicals industry in India. Total returns to shareholders of 444% over the past three years.Valuation Update With 7 Day Price Move • Dec 23Investor sentiment improved over the past weekAfter last week's 19% share price gain to ₹48.45, the stock trades at a trailing P/E ratio of 13.1x. Average trailing P/E is 20x in the Chemicals industry in India. Total returns to shareholders of 294% over the past three years.Reported Earnings • Nov 20Second quarter 2023 earnings released: EPS: ₹2.16 (vs ₹0.94 in 2Q 2022)Second quarter 2023 results: EPS: ₹2.16 (up from ₹0.94 in 2Q 2022). Revenue: ₹90.8m (down 39% from 2Q 2022). Net income: ₹9.61m (up 130% from 2Q 2022). Profit margin: 11% (up from 2.8% in 2Q 2022). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 37% per year but the company’s share price has increased by 43% per year, which means it is tracking significantly ahead of earnings growth.Valuation Update With 7 Day Price Move • Nov 11Investor sentiment improved over the past weekAfter last week's 25% share price gain to ₹49.60, the stock trades at a trailing P/E ratio of 20x. Average trailing P/E is 19x in the Chemicals industry in India. Total returns to shareholders of 272% over the past three years.お知らせ • Nov 06Link Pharma Chem Limited to Report Q2, 2023 Results on Nov 14, 2022Link Pharma Chem Limited announced that they will report Q2, 2023 results on Nov 14, 2022お知らせ • Sep 17Link Pharma Chem Limited Announces Executive ChangesThe board of directors of Link Pharma Chem Limited in its meeting held on September 16, 2022, approved the Resignation Letter from Mr. Bhushan Ravindra Joshi (Membership No.: A40085) from the post of Company Secretary & Compliance Officer of the Company effective from closure of business hours on September 17, 2022. Appointment of Ms. Khushbu Prakashbhai Patel (Membership No.: A65182) as Company Secretary and Compliance Office of the Company effective from September 19, 2022, under Section 203 of Companies Act, 2013 and under Regulation 6 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 and Regulation 9(3) of SEBI (Prohibition of Insider Trading) Regulations, 2015. Brief profile of Khushbu Prakashbhai Patel: Ms. Khushbu Prakashbhai Patel is an Associate Member of the Institute of Company Secretaries of India having Membership No. A65182. She is also Master in Commerce, Bachelors in Law and Bachelors of Business Administration and having experience of Corporate Laws, Listing Regulations etc.Reported Earnings • Aug 18First quarter 2023 earnings released: ₹0.66 loss per share (vs ₹1.10 profit in 1Q 2022)First quarter 2023 results: ₹0.66 loss per share (down from ₹1.10 profit in 1Q 2022). Revenue: ₹108.2m (down 19% from 1Q 2022). Net loss: ₹2.93m (down 160% from profit in 1Q 2022). Over the last 3 years on average, earnings per share has increased by 38% per year but the company’s share price has increased by 49% per year, which means it is tracking significantly ahead of earnings growth.Reported Earnings • Jul 14Full year 2022 earnings released: EPS: ₹4.24 (vs ₹2.44 in FY 2021)Full year 2022 results: EPS: ₹4.24 (up from ₹2.44 in FY 2021). Revenue: ₹535.6m (up 54% from FY 2021). Net income: ₹18.8m (up 74% from FY 2021). Profit margin: 3.5% (up from 3.1% in FY 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 44% per year but the company’s share price has increased by 54% per year, which means it is tracking significantly ahead of earnings growth.お知らせ • Jul 12Link Pharma Chem Limited, Annual General Meeting, Aug 05, 2022Link Pharma Chem Limited, Annual General Meeting, Aug 05, 2022, at 11:00 Indian Standard Time. Agenda: To consider and adopt the Audited Financial Statements for the Financial Year ended March 31, 2022 and the Reports of the Board of Directors and Auditors thereon; to appoint a Director in place of Mr. Satish Thakur, (DIN: 00292129) who retires by rotation and, being eligible, offers himself for re-appointment; and to consider appointment of Statutory Auditors of the Company.Reported Earnings • Jun 03Full year 2022 earnings released: EPS: ₹4.24 (vs ₹2.44 in FY 2021)Full year 2022 results: EPS: ₹4.24 (up from ₹2.44 in FY 2021). Revenue: ₹540.3m (up 55% from FY 2021). Net income: ₹18.8m (up 74% from FY 2021). Profit margin: 3.5% (up from 3.1% in FY 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 44% per year but the company’s share price has only increased by 28% per year, which means it is significantly lagging earnings growth.お知らせ • May 21Link Pharma Chem Limited to Report Q4, 2022 Results on May 30, 2022Link Pharma Chem Limited announced that they will report Q4, 2022 results on May 30, 2022Valuation Update With 7 Day Price Move • May 10Investor sentiment deteriorated over the past weekAfter last week's 19% share price decline to ₹41.85, the stock trades at a trailing P/E ratio of 10.5x. Average trailing P/E is 19x in the Chemicals industry in India. Total returns to shareholders of 109% over the past three years.Valuation Update With 7 Day Price Move • Apr 05Investor sentiment improved over the past weekAfter last week's 15% share price gain to ₹42.90, the stock trades at a trailing P/E ratio of 10.8x. Average trailing P/E is 20x in the Chemicals industry in India. Total returns to shareholders of 87% over the past three years.Valuation Update With 7 Day Price Move • Feb 21Investor sentiment deteriorated over the past weekAfter last week's 15% share price decline to ₹40.75, the stock trades at a trailing P/E ratio of 10.3x. Average trailing P/E is 19x in the Chemicals industry in India. Total returns to shareholders of 102% over the past three years.お知らせ • Feb 15Link Pharma Chem Limited Announces Appointment of Jayesh Pushpavadan Jani as Chief Financial Officer, Effective February 15, 2022Link Pharma Chem Limited announced that Mr. Jayesh Pushpavadan Jani has appointed as Chief Financial Officer (KMP) of the Company from the start of business hours on 15th February, 2022.Reported Earnings • Feb 15Third quarter 2022 earnings: Revenues and EPS in line with analyst expectationsThird quarter 2022 results: EPS: ₹1.58 (up from ₹0.76 in 3Q 2021). Revenue: ₹143.5m (up 45% from 3Q 2021). Net income: ₹7.02m (up 109% from 3Q 2021). Profit margin: 4.9% (up from 3.4% in 3Q 2021). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has increased by 30% per year whereas the company’s share price has increased by 29% per year.Valuation Update With 7 Day Price Move • Dec 23Investor sentiment improved over the past weekAfter last week's 20% share price gain to ₹40.85, the stock trades at a trailing P/E ratio of 13x. Average trailing P/E is 18x in the Chemicals industry in India. Total returns to shareholders of 59% over the past three years.Reported Earnings • Aug 04Full year 2021 earnings released: EPS ₹2.44 (vs ₹2.14 in FY 2020)The company reported a solid full year result with improved earnings and revenues, although profit margins were weaker. Full year 2021 results: Revenue: ₹348.1m (up 37% from FY 2020). Net income: ₹10.8m (up 14% from FY 2020). Profit margin: 3.1% (down from 3.7% in FY 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 3% per year but the company’s share price has increased by 8% per year, which means it is well ahead of earnings.Valuation Update With 7 Day Price Move • Jun 05Investor sentiment improved over the past weekAfter last week's 16% share price gain to ₹37.45, the stock trades at a trailing P/E ratio of 15.3x. Average trailing P/E is 20x in the Chemicals industry in India. Total returns to shareholders of 23% over the past three years.Reported Earnings • May 30Full year 2021 earnings released: EPS ₹2.44 (vs ₹2.14 in FY 2020)The company reported a solid full year result with improved earnings and revenues, although profit margins were weaker. Full year 2021 results: Revenue: ₹348.3m (up 37% from FY 2020). Net income: ₹10.8m (up 14% from FY 2020). Profit margin: 3.1% (down from 3.7% in FY 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 3% per year whereas the company’s share price has remained flat.Valuation Update With 7 Day Price Move • Apr 24Investor sentiment improved over the past weekAfter last week's 44% share price gain to ₹36.00, the stock trades at a trailing P/E ratio of 13.1x. Average trailing P/E is 17x in the Chemicals industry in India. Total loss to shareholders of 17% over the past three years.Reported Earnings • Feb 17Third quarter 2021 earnings released: EPS ₹0.76 (vs ₹0.79 in 3Q 2020)The company reported a mediocre third quarter result with weaker earnings and profit margins, although revenues improved. Third quarter 2021 results: Revenue: ₹99.1m (up 35% from 3Q 2020). Net income: ₹3.37m (down 4.5% from 3Q 2020). Profit margin: 3.4% (down from 4.8% in 3Q 2020). Over the last 3 years on average, earnings per share has fallen by 7% per year whereas the company’s share price has fallen by 12% per year.お知らせ • Feb 04Link Pharma Chem Limited to Report Q3, 2021 Results on Feb 12, 2021Link Pharma Chem Limited announced that they will report Q3, 2021 results on Feb 12, 2021Valuation Update With 7 Day Price Move • Jan 29Investor sentiment improved over the past weekAfter last week's 17% share price gain to ₹26.50, the stock is trading at a trailing P/E ratio of 9.5x, up from the previous P/E ratio of 8.1x. This compares to an average P/E of 18x in the Chemicals industry in India. Total return to shareholders over the past three years is a loss of 30%.Is New 90 Day High Low • Jan 27New 90-day low: ₹20.10The company is down 9.0% from its price of ₹22.10 on 29 October 2020. The Indian market is up 22% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 17% over the same period.Is New 90 Day High Low • Dec 16New 90-day high: ₹26.65The company is up 17% from its price of ₹22.80 on 17 September 2020. The Indian market is up 15% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 12% over the same period.Valuation Update With 7 Day Price Move • Dec 16Investor sentiment improved over the past weekAfter last week's 18% share price gain to ₹26.65, the stock is trading at a trailing P/E ratio of 9.6x, up from the previous P/E ratio of 8.1x. This compares to an average P/E of 18x in the Chemicals industry in India. Total returns to shareholders over the past three years are 33%.Reported Earnings • Nov 13Second quarter 2021 earnings released: EPS ₹0.60The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: ₹85.6m (up 27% from 2Q 2020). Net income: ₹2.67m (up 406% from 2Q 2020). Profit margin: 3.1% (up from 0.8% in 2Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 6% per year but the company’s share price has increased by 6% per year, which means it is well ahead of earnings.Is New 90 Day High Low • Nov 10New 90-day high: ₹25.00The company is up 34% from its price of ₹18.60 on 12 August 2020. The Indian market is up 8.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 12% over the same period.Is New 90 Day High Low • Oct 06New 90-day high: ₹24.95The company is up 73% from its price of ₹14.40 on 08 July 2020. The Indian market is up 7.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 13% over the same period.お知らせ • Sep 26Link Pharma Chem Limited Appoints Rishikesh Thakur as Managing DirectorLink Pharma Chem Limited announced that Mr. Rishikesh Thakur has been appointed as Managing Director of the Company for period of three years with effect from September 24, 2020.株主還元524748IN ChemicalsIN 市場7D3.4%0.7%0.5%1Y-15.3%-2.6%-0.7%株主還元を見る業界別リターン: 524748過去 1 年間で-2.6 % の収益を上げたIndian Chemicals業界を下回りました。リターン対市場: 524748は、過去 1 年間で-0.7 % のリターンを上げたIndian市場を下回りました。価格変動Is 524748's price volatile compared to industry and market?524748 volatility524748 Average Weekly Movement11.2%Chemicals Industry Average Movement7.2%Market Average Movement7.2%10% most volatile stocks in IN Market10.1%10% least volatile stocks in IN Market4.8%安定した株価: 524748の株価は、 Indian市場と比較して過去 3 か月間で変動しています。時間の経過による変動: 524748の weekly volatility ( 11% ) は過去 1 年間安定していますが、依然としてIndianの株式の 75% よりも高くなっています。会社概要設立従業員CEO（最高経営責任者ウェブサイト198483Rishikesh Thakurwww.linkpharmachem.co.inリンク・ファーマ・ケム・リミテッドは、インドで製薬、農業、特殊化学品産業向けの有機中間体の製造・販売を行っている。また、中小・大企業向けの多段階合成の受託合成・受託製造、有機合成の多段階パスウェイの開発、既存の合成法の改良・最適化も行っている。また、製品の輸出も行っている。リンク・ファーマ・ケム・リミテッドは1984年に設立され、インドのヴァドダラに拠点を置く。もっと見るLink Pharma Chem Limited 基礎のまとめLink Pharma Chem の収益と売上を時価総額と比較するとどうか。524748 基礎統計学時価総額₹132.68m収益（TTM）₹1.35m売上高(TTM)₹272.89m98.1xPER（株価収益率0.5xP/Sレシオ524748 は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計524748 損益計算書（TTM）収益₹272.89m売上原価₹116.81m売上総利益₹156.08mその他の費用₹154.73m収益₹1.35m直近の収益報告Dec 31, 2025次回決算日該当なし一株当たり利益（EPS）0.30グロス・マージン57.20%純利益率0.50%有利子負債／自己資本比率61.9%524748 の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/21 19:56終値2026/05/21 00:00収益2025/12/31年間収益2025/03/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Link Pharma Chem Limited 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • May 14Link Pharma Chem Limited to Report Q4, 2026 Results on May 21, 2026Link Pharma Chem Limited announced that they will report Q4, 2026 results on May 21, 2026
Valuation Update With 7 Day Price Move • Mar 16Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to ₹23.40, the stock trades at a trailing P/E ratio of 76.8x. Average trailing P/E is 21x in the Chemicals industry in India. Total loss to shareholders of 39% over the past three years.
Recent Insider Transactions • Mar 15Whole-Time Chairman recently bought ₹1.0m worth of stockOn the 13th of March, Satish Thakur bought around 41k shares on-market at roughly ₹25.21 per share. This transaction amounted to 4.3% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was Satish's only on-market trade for the last 12 months.
Reported Earnings • Feb 16Third quarter 2026 earnings released: EPS: ₹0.15 (vs ₹1.50 loss in 3Q 2025)Third quarter 2026 results: EPS: ₹0.15 (up from ₹1.50 loss in 3Q 2025). Revenue: ₹65.3m (up 22% from 3Q 2025). Net income: ₹682.0k (up ₹7.35m from 3Q 2025). Profit margin: 1.0% (up from net loss in 3Q 2025). Over the last 3 years on average, earnings per share has fallen by 25% per year but the company’s share price has only fallen by 13% per year, which means it has not declined as severely as earnings.
お知らせ • Feb 07Link Pharma Chem Limited to Report Q3, 2026 Results on Feb 14, 2026Link Pharma Chem Limited announced that they will report Q3, 2026 results at 9:15 AM, Indian Standard Time on Feb 14, 2026
New Risk • Jan 28New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Indian stocks, typically moving 8.7% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (15% operating cash flow to total debt). Share price has been highly volatile over the past 3 months (8.7% average weekly change). Earnings have declined by 52% per year over the past 5 years. Market cap is less than US$10m (₹126.3m market cap, or US$1.37m). Minor Risk Revenue is less than US$5m (₹259m revenue, or US$2.8m).
お知らせ • May 14Link Pharma Chem Limited to Report Q4, 2026 Results on May 21, 2026Link Pharma Chem Limited announced that they will report Q4, 2026 results on May 21, 2026
Valuation Update With 7 Day Price Move • Mar 16Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to ₹23.40, the stock trades at a trailing P/E ratio of 76.8x. Average trailing P/E is 21x in the Chemicals industry in India. Total loss to shareholders of 39% over the past three years.
Recent Insider Transactions • Mar 15Whole-Time Chairman recently bought ₹1.0m worth of stockOn the 13th of March, Satish Thakur bought around 41k shares on-market at roughly ₹25.21 per share. This transaction amounted to 4.3% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was Satish's only on-market trade for the last 12 months.
Reported Earnings • Feb 16Third quarter 2026 earnings released: EPS: ₹0.15 (vs ₹1.50 loss in 3Q 2025)Third quarter 2026 results: EPS: ₹0.15 (up from ₹1.50 loss in 3Q 2025). Revenue: ₹65.3m (up 22% from 3Q 2025). Net income: ₹682.0k (up ₹7.35m from 3Q 2025). Profit margin: 1.0% (up from net loss in 3Q 2025). Over the last 3 years on average, earnings per share has fallen by 25% per year but the company’s share price has only fallen by 13% per year, which means it has not declined as severely as earnings.
お知らせ • Feb 07Link Pharma Chem Limited to Report Q3, 2026 Results on Feb 14, 2026Link Pharma Chem Limited announced that they will report Q3, 2026 results at 9:15 AM, Indian Standard Time on Feb 14, 2026
New Risk • Jan 28New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Indian stocks, typically moving 8.7% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (15% operating cash flow to total debt). Share price has been highly volatile over the past 3 months (8.7% average weekly change). Earnings have declined by 52% per year over the past 5 years. Market cap is less than US$10m (₹126.3m market cap, or US$1.37m). Minor Risk Revenue is less than US$5m (₹259m revenue, or US$2.8m).
Reported Earnings • Nov 15Second quarter 2026 earnings released: EPS: ₹0.03 (vs ₹0.69 loss in 2Q 2025)Second quarter 2026 results: EPS: ₹0.03 (up from ₹0.69 loss in 2Q 2025). Revenue: ₹63.4m (up 32% from 2Q 2025). Net income: ₹156.0k (up ₹3.22m from 2Q 2025). Profit margin: 0.2% (up from net loss in 2Q 2025). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 61% per year but the company’s share price has only fallen by 5% per year, which means it has not declined as severely as earnings.
お知らせ • Nov 08Link Pharma Chem Limited to Report Q2, 2026 Results on Nov 13, 2025Link Pharma Chem Limited announced that they will report Q2, 2026 results on Nov 13, 2025
New Risk • Oct 07New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Indian stocks, typically moving 8.3% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (8.3% average weekly change). Earnings have declined by 50% per year over the past 5 years. Market cap is less than US$10m (₹154.3m market cap, or US$1.74m). Minor Risks High level of debt (45% net debt to equity). Revenue is less than US$5m (₹244m revenue, or US$2.7m).
お知らせ • Aug 13Link Pharma Chem Limited, Annual General Meeting, Sep 09, 2025Link Pharma Chem Limited, Annual General Meeting, Sep 09, 2025, at 11:30 Indian Standard Time.
Reported Earnings • Aug 02First quarter 2026 earnings released: EPS: ₹0.91 (vs ₹0.67 in 1Q 2025)First quarter 2026 results: EPS: ₹0.91 (up from ₹0.67 in 1Q 2025). Revenue: ₹80.2m (down 9.3% from 1Q 2025). Net income: ₹4.02m (up 36% from 1Q 2025). Profit margin: 5.0% (up from 3.4% in 1Q 2025). The increase in margin was driven by lower expenses. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 65 percentage points per year, which is a significant difference in performance.
お知らせ • Jul 24Link Pharma Chem Limited to Report Q1, 2026 Results on Aug 01, 2025Link Pharma Chem Limited announced that they will report Q1, 2026 results on Aug 01, 2025
New Risk • Jun 29New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 46% per year over the past 5 years. Market cap is less than US$10m (₹168.7m market cap, or US$1.97m). Minor Risks High level of debt (45% net debt to equity). Share price has been volatile over the past 3 months (7.6% average weekly change). Revenue is less than US$5m (₹254m revenue, or US$3.0m).
Reported Earnings • May 28Full year 2025 earnings released: ₹2.31 loss per share (vs ₹3.07 loss in FY 2024)Full year 2025 results: ₹2.31 loss per share (improved from ₹3.07 loss in FY 2024). Revenue: ₹256.2m (down 14% from FY 2024). Net loss: ₹10.3m (loss narrowed 25% from FY 2024). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 76 percentage points per year, which is a significant difference in performance.
お知らせ • May 19Link Pharma Chem Limited to Report Q4, 2025 Results on May 27, 2025Link Pharma Chem Limited announced that they will report Q4, 2025 results on May 27, 2025
New Risk • Apr 29New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (0.4x net interest cover). Earnings have declined by 38% per year over the past 5 years. Market cap is less than US$10m (₹159.0m market cap, or US$1.87m). Minor Risks Share price has been volatile over the past 3 months (8.7% average weekly change). Revenue is less than US$5m (₹270m revenue, or US$3.2m).
Reported Earnings • Feb 08Third quarter 2025 earnings released: ₹1.50 loss per share (vs ₹0.50 profit in 3Q 2024)Third quarter 2025 results: ₹1.50 loss per share (down from ₹0.50 profit in 3Q 2024). Revenue: ₹47.8m (down 40% from 3Q 2024). Net loss: ₹6.67m (down 402% from profit in 3Q 2024). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 78 percentage points per year, which is a significant difference in performance.
お知らせ • Jan 28Link Pharma Chem Limited to Report Q3, 2025 Results on Feb 07, 2025Link Pharma Chem Limited announced that they will report Q3, 2025 results on Feb 07, 2025
Reported Earnings • Nov 13Second quarter 2025 earnings released: ₹0.69 loss per share (vs ₹2.30 loss in 2Q 2024)Second quarter 2025 results: ₹0.69 loss per share (improved from ₹2.30 loss in 2Q 2024). Revenue: ₹51.6m (down 14% from 2Q 2024). Net loss: ₹3.06m (loss narrowed 70% from 2Q 2024). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 89 percentage points per year, which is a significant difference in performance.
お知らせ • Oct 31Link Pharma Chem Limited to Report Q2, 2025 Results on Nov 11, 2024Link Pharma Chem Limited announced that they will report Q2, 2025 results on Nov 11, 2024
お知らせ • Oct 06Link Pharma Chem Limited Announces Cessation of DirectorsLink Pharma Chem Limited informed that Mr. Suresh Balram Dhatrak (DIN: 00365256) and Mr. Devang Uttamchand Shah (DIN: 00704950), Independent directors have completed their tenure of 10 years i.e second term on 26th September, 2024 and consequently ceased to be an Independent Directors of the Company w.e.f. close of business hours on 26th September, 2024.
お知らせ • Sep 05Link Pharma Chem Limited, Annual General Meeting, Sep 27, 2024Link Pharma Chem Limited, Annual General Meeting, Sep 27, 2024, at 11:30 Indian Standard Time.
Reported Earnings • Aug 10First quarter 2025 earnings released: EPS: ₹0.67 (vs ₹1.85 loss in 1Q 2024)First quarter 2025 results: EPS: ₹0.67 (up from ₹1.85 loss in 1Q 2024). Revenue: ₹91.2m (up 16% from 1Q 2024). Net income: ₹2.96m (up ₹11.2m from 1Q 2024). Profit margin: 3.3% (up from net loss in 1Q 2024). The move to profitability was driven by higher revenue. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 97 percentage points per year, which is a significant difference in performance.
お知らせ • Aug 02Link Pharma Chem Limited to Report Q1, 2025 Results on Aug 09, 2024Link Pharma Chem Limited announced that they will report Q1, 2025 results on Aug 09, 2024
Reported Earnings • Jun 04Full year 2024 earnings released: ₹3.07 loss per share (vs ₹1.47 profit in FY 2023)Full year 2024 results: ₹3.07 loss per share (down from ₹1.47 profit in FY 2023). Revenue: ₹305.4m (down 21% from FY 2023). Net loss: ₹13.6m (down 308% from profit in FY 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 86 percentage points per year, which is a significant difference in performance.
お知らせ • May 23Link Pharma Chem Limited to Report Q4, 2024 Results on May 29, 2024Link Pharma Chem Limited announced that they will report Q4, 2024 results on May 29, 2024
Reported Earnings • Feb 11Third quarter 2024 earnings released: EPS: ₹0.50 (vs ₹0.40 in 3Q 2023)Third quarter 2024 results: EPS: ₹0.50 (up from ₹0.40 in 3Q 2023). Revenue: ₹83.1m (down 11% from 3Q 2023). Net income: ₹2.21m (up 23% from 3Q 2023). Profit margin: 2.7% (up from 1.9% in 3Q 2023). The increase in margin was driven by lower expenses. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 88 percentage points per year, which is a significant difference in performance.
お知らせ • Feb 01Link Pharma Chem Limited to Report Q3, 2024 Results on Feb 09, 2024Link Pharma Chem Limited announced that they will report Q3, 2024 results on Feb 09, 2024
Reported Earnings • Nov 10Second quarter 2024 earnings released: ₹2.30 loss per share (vs ₹2.16 profit in 2Q 2023)Second quarter 2024 results: ₹2.30 loss per share (down from ₹2.16 profit in 2Q 2023). Revenue: ₹60.2m (down 29% from 2Q 2023). Net loss: ₹10.2m (down 206% from profit in 2Q 2023). Over the last 3 years on average, earnings per share has fallen by 46% per year but the company’s share price has increased by 24% per year, which means it is well ahead of earnings.
お知らせ • Nov 09Link Pharma Chem Limited Announces CFO ChangesLink Pharma Chem Limited informed that Mr. Sanjib Dutta has appointed as Chief Financial Officer (KMP) of the Company with effect from 08th November, 2023 at the meeting of Board of Directors held on 8th November, 2023. Mr. Sanjib Dutta is Commerce Graduate from Calcutta University, and having 27 Years of Work-Experience in Company Accounts, Banking, Goods and Services Tax, Commercial Part & Statutory Compliances etc.
Board Change • Nov 07Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 2 highly experienced directors. Independent Director Rachna Ghai was the last director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
お知らせ • Nov 01Link Pharma Chem Limited Announces Resignation of Mr. Jayesh Pushpavadan Jani as Chief Financial OfficerLink Pharma Chem Limited announced that Mr. Jayesh Pushpavadan Jani has tendered his resignation from the post of Chief Financial Officer (KMP) of the Company with effect from 31st October, 2023 (closing business hours) due to almost attaining the age of retirement.
お知らせ • Aug 29Link Pharma Chem Limited, Annual General Meeting, Sep 21, 2023Link Pharma Chem Limited, Annual General Meeting, Sep 21, 2023, at 11:30 Indian Standard Time. Agenda: To consider and adopt the Audited Financial Statements for the Financial Year ended March 31, 2023 and the Reports of the Board of Directors and Auditors thereon; to appoint a director in place of Mr. Rishikesh Thakur, who retires by rotation and, being eligible, offers himself for re-appointment; to consider appointment of Mr. Satish G. Thakur as a Chairman & Whole-time Director; and to consider other matters.
お知らせ • Aug 06Link Pharma Chem Limited to Report Q1, 2024 Results on Aug 14, 2023Link Pharma Chem Limited announced that they will report Q1, 2024 results on Aug 14, 2023
お知らせ • Jul 12Link Pharma Chem Limited Announces Disruption in Operation at Nandesari Plant of the Company Due to Closure Notice from Gujarat Pollution Control BoardLink Pharma Chem Limited has received notice from the Gujarat Pollution Control Board, Gandhinagar effecting closure of operations of its plant situated at Nandesari, Dist. Vadodara. Gujarat Pollution Control Board (GPCB) has laid certain conditions and has asked the Company to fulfil the same. The Company after analyzing order has started taking effective steps as directed by the GPCB to seek relief against the order.
Reported Earnings • May 31Full year 2023 earnings released: EPS: ₹1.47 (vs ₹4.24 in FY 2022)Full year 2023 results: EPS: ₹1.47 (down from ₹4.24 in FY 2022). Revenue: ₹386.1m (down 28% from FY 2022). Net income: ₹6.54m (down 65% from FY 2022). Profit margin: 1.7% (down from 3.5% in FY 2022). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 4% per year but the company’s share price has increased by 33% per year, which means it is tracking significantly ahead of earnings growth.
お知らせ • May 20Link Pharma Chem Limited to Report Q4, 2023 Results on May 29, 2023Link Pharma Chem Limited announced that they will report Q4, 2023 results on May 29, 2023
Reported Earnings • Feb 12Third quarter 2023 earnings released: EPS: ₹0.40 (vs ₹1.58 in 3Q 2022)Third quarter 2023 results: EPS: ₹0.40 (down from ₹1.58 in 3Q 2022). Revenue: ₹93.6m (down 33% from 3Q 2022). Net income: ₹1.79m (down 75% from 3Q 2022). Profit margin: 1.9% (down from 5.0% in 3Q 2022). Over the last 3 years on average, earnings per share has increased by 24% per year but the company’s share price has increased by 46% per year, which means it is tracking significantly ahead of earnings growth.
お知らせ • Feb 03Link Pharma Chem Limited to Report Q3, 2023 Results on Feb 09, 2023Link Pharma Chem Limited announced that they will report Q3, 2023 results on Feb 09, 2023
Valuation Update With 7 Day Price Move • Jan 27Investor sentiment deteriorates as stock falls 20%After last week's 20% share price decline to ₹56.95, the stock trades at a trailing P/E ratio of 15.4x. Average trailing P/E is 19x in the Chemicals industry in India. Total returns to shareholders of 307% over the past three years.
Valuation Update With 7 Day Price Move • Jan 10Investor sentiment improved over the past weekAfter last week's 18% share price gain to ₹67.20, the stock trades at a trailing P/E ratio of 18.1x. Average trailing P/E is 19x in the Chemicals industry in India. Total returns to shareholders of 444% over the past three years.
Valuation Update With 7 Day Price Move • Dec 23Investor sentiment improved over the past weekAfter last week's 19% share price gain to ₹48.45, the stock trades at a trailing P/E ratio of 13.1x. Average trailing P/E is 20x in the Chemicals industry in India. Total returns to shareholders of 294% over the past three years.
Reported Earnings • Nov 20Second quarter 2023 earnings released: EPS: ₹2.16 (vs ₹0.94 in 2Q 2022)Second quarter 2023 results: EPS: ₹2.16 (up from ₹0.94 in 2Q 2022). Revenue: ₹90.8m (down 39% from 2Q 2022). Net income: ₹9.61m (up 130% from 2Q 2022). Profit margin: 11% (up from 2.8% in 2Q 2022). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 37% per year but the company’s share price has increased by 43% per year, which means it is tracking significantly ahead of earnings growth.
Valuation Update With 7 Day Price Move • Nov 11Investor sentiment improved over the past weekAfter last week's 25% share price gain to ₹49.60, the stock trades at a trailing P/E ratio of 20x. Average trailing P/E is 19x in the Chemicals industry in India. Total returns to shareholders of 272% over the past three years.
お知らせ • Nov 06Link Pharma Chem Limited to Report Q2, 2023 Results on Nov 14, 2022Link Pharma Chem Limited announced that they will report Q2, 2023 results on Nov 14, 2022
お知らせ • Sep 17Link Pharma Chem Limited Announces Executive ChangesThe board of directors of Link Pharma Chem Limited in its meeting held on September 16, 2022, approved the Resignation Letter from Mr. Bhushan Ravindra Joshi (Membership No.: A40085) from the post of Company Secretary & Compliance Officer of the Company effective from closure of business hours on September 17, 2022. Appointment of Ms. Khushbu Prakashbhai Patel (Membership No.: A65182) as Company Secretary and Compliance Office of the Company effective from September 19, 2022, under Section 203 of Companies Act, 2013 and under Regulation 6 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 and Regulation 9(3) of SEBI (Prohibition of Insider Trading) Regulations, 2015. Brief profile of Khushbu Prakashbhai Patel: Ms. Khushbu Prakashbhai Patel is an Associate Member of the Institute of Company Secretaries of India having Membership No. A65182. She is also Master in Commerce, Bachelors in Law and Bachelors of Business Administration and having experience of Corporate Laws, Listing Regulations etc.
Reported Earnings • Aug 18First quarter 2023 earnings released: ₹0.66 loss per share (vs ₹1.10 profit in 1Q 2022)First quarter 2023 results: ₹0.66 loss per share (down from ₹1.10 profit in 1Q 2022). Revenue: ₹108.2m (down 19% from 1Q 2022). Net loss: ₹2.93m (down 160% from profit in 1Q 2022). Over the last 3 years on average, earnings per share has increased by 38% per year but the company’s share price has increased by 49% per year, which means it is tracking significantly ahead of earnings growth.
Reported Earnings • Jul 14Full year 2022 earnings released: EPS: ₹4.24 (vs ₹2.44 in FY 2021)Full year 2022 results: EPS: ₹4.24 (up from ₹2.44 in FY 2021). Revenue: ₹535.6m (up 54% from FY 2021). Net income: ₹18.8m (up 74% from FY 2021). Profit margin: 3.5% (up from 3.1% in FY 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 44% per year but the company’s share price has increased by 54% per year, which means it is tracking significantly ahead of earnings growth.
お知らせ • Jul 12Link Pharma Chem Limited, Annual General Meeting, Aug 05, 2022Link Pharma Chem Limited, Annual General Meeting, Aug 05, 2022, at 11:00 Indian Standard Time. Agenda: To consider and adopt the Audited Financial Statements for the Financial Year ended March 31, 2022 and the Reports of the Board of Directors and Auditors thereon; to appoint a Director in place of Mr. Satish Thakur, (DIN: 00292129) who retires by rotation and, being eligible, offers himself for re-appointment; and to consider appointment of Statutory Auditors of the Company.
Reported Earnings • Jun 03Full year 2022 earnings released: EPS: ₹4.24 (vs ₹2.44 in FY 2021)Full year 2022 results: EPS: ₹4.24 (up from ₹2.44 in FY 2021). Revenue: ₹540.3m (up 55% from FY 2021). Net income: ₹18.8m (up 74% from FY 2021). Profit margin: 3.5% (up from 3.1% in FY 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 44% per year but the company’s share price has only increased by 28% per year, which means it is significantly lagging earnings growth.
お知らせ • May 21Link Pharma Chem Limited to Report Q4, 2022 Results on May 30, 2022Link Pharma Chem Limited announced that they will report Q4, 2022 results on May 30, 2022
Valuation Update With 7 Day Price Move • May 10Investor sentiment deteriorated over the past weekAfter last week's 19% share price decline to ₹41.85, the stock trades at a trailing P/E ratio of 10.5x. Average trailing P/E is 19x in the Chemicals industry in India. Total returns to shareholders of 109% over the past three years.
Valuation Update With 7 Day Price Move • Apr 05Investor sentiment improved over the past weekAfter last week's 15% share price gain to ₹42.90, the stock trades at a trailing P/E ratio of 10.8x. Average trailing P/E is 20x in the Chemicals industry in India. Total returns to shareholders of 87% over the past three years.
Valuation Update With 7 Day Price Move • Feb 21Investor sentiment deteriorated over the past weekAfter last week's 15% share price decline to ₹40.75, the stock trades at a trailing P/E ratio of 10.3x. Average trailing P/E is 19x in the Chemicals industry in India. Total returns to shareholders of 102% over the past three years.
お知らせ • Feb 15Link Pharma Chem Limited Announces Appointment of Jayesh Pushpavadan Jani as Chief Financial Officer, Effective February 15, 2022Link Pharma Chem Limited announced that Mr. Jayesh Pushpavadan Jani has appointed as Chief Financial Officer (KMP) of the Company from the start of business hours on 15th February, 2022.
Reported Earnings • Feb 15Third quarter 2022 earnings: Revenues and EPS in line with analyst expectationsThird quarter 2022 results: EPS: ₹1.58 (up from ₹0.76 in 3Q 2021). Revenue: ₹143.5m (up 45% from 3Q 2021). Net income: ₹7.02m (up 109% from 3Q 2021). Profit margin: 4.9% (up from 3.4% in 3Q 2021). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has increased by 30% per year whereas the company’s share price has increased by 29% per year.
Valuation Update With 7 Day Price Move • Dec 23Investor sentiment improved over the past weekAfter last week's 20% share price gain to ₹40.85, the stock trades at a trailing P/E ratio of 13x. Average trailing P/E is 18x in the Chemicals industry in India. Total returns to shareholders of 59% over the past three years.
Reported Earnings • Aug 04Full year 2021 earnings released: EPS ₹2.44 (vs ₹2.14 in FY 2020)The company reported a solid full year result with improved earnings and revenues, although profit margins were weaker. Full year 2021 results: Revenue: ₹348.1m (up 37% from FY 2020). Net income: ₹10.8m (up 14% from FY 2020). Profit margin: 3.1% (down from 3.7% in FY 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 3% per year but the company’s share price has increased by 8% per year, which means it is well ahead of earnings.
Valuation Update With 7 Day Price Move • Jun 05Investor sentiment improved over the past weekAfter last week's 16% share price gain to ₹37.45, the stock trades at a trailing P/E ratio of 15.3x. Average trailing P/E is 20x in the Chemicals industry in India. Total returns to shareholders of 23% over the past three years.
Reported Earnings • May 30Full year 2021 earnings released: EPS ₹2.44 (vs ₹2.14 in FY 2020)The company reported a solid full year result with improved earnings and revenues, although profit margins were weaker. Full year 2021 results: Revenue: ₹348.3m (up 37% from FY 2020). Net income: ₹10.8m (up 14% from FY 2020). Profit margin: 3.1% (down from 3.7% in FY 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 3% per year whereas the company’s share price has remained flat.
Valuation Update With 7 Day Price Move • Apr 24Investor sentiment improved over the past weekAfter last week's 44% share price gain to ₹36.00, the stock trades at a trailing P/E ratio of 13.1x. Average trailing P/E is 17x in the Chemicals industry in India. Total loss to shareholders of 17% over the past three years.
Reported Earnings • Feb 17Third quarter 2021 earnings released: EPS ₹0.76 (vs ₹0.79 in 3Q 2020)The company reported a mediocre third quarter result with weaker earnings and profit margins, although revenues improved. Third quarter 2021 results: Revenue: ₹99.1m (up 35% from 3Q 2020). Net income: ₹3.37m (down 4.5% from 3Q 2020). Profit margin: 3.4% (down from 4.8% in 3Q 2020). Over the last 3 years on average, earnings per share has fallen by 7% per year whereas the company’s share price has fallen by 12% per year.
お知らせ • Feb 04Link Pharma Chem Limited to Report Q3, 2021 Results on Feb 12, 2021Link Pharma Chem Limited announced that they will report Q3, 2021 results on Feb 12, 2021
Valuation Update With 7 Day Price Move • Jan 29Investor sentiment improved over the past weekAfter last week's 17% share price gain to ₹26.50, the stock is trading at a trailing P/E ratio of 9.5x, up from the previous P/E ratio of 8.1x. This compares to an average P/E of 18x in the Chemicals industry in India. Total return to shareholders over the past three years is a loss of 30%.
Is New 90 Day High Low • Jan 27New 90-day low: ₹20.10The company is down 9.0% from its price of ₹22.10 on 29 October 2020. The Indian market is up 22% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 17% over the same period.
Is New 90 Day High Low • Dec 16New 90-day high: ₹26.65The company is up 17% from its price of ₹22.80 on 17 September 2020. The Indian market is up 15% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 12% over the same period.
Valuation Update With 7 Day Price Move • Dec 16Investor sentiment improved over the past weekAfter last week's 18% share price gain to ₹26.65, the stock is trading at a trailing P/E ratio of 9.6x, up from the previous P/E ratio of 8.1x. This compares to an average P/E of 18x in the Chemicals industry in India. Total returns to shareholders over the past three years are 33%.
Reported Earnings • Nov 13Second quarter 2021 earnings released: EPS ₹0.60The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: ₹85.6m (up 27% from 2Q 2020). Net income: ₹2.67m (up 406% from 2Q 2020). Profit margin: 3.1% (up from 0.8% in 2Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 6% per year but the company’s share price has increased by 6% per year, which means it is well ahead of earnings.
Is New 90 Day High Low • Nov 10New 90-day high: ₹25.00The company is up 34% from its price of ₹18.60 on 12 August 2020. The Indian market is up 8.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 12% over the same period.
Is New 90 Day High Low • Oct 06New 90-day high: ₹24.95The company is up 73% from its price of ₹14.40 on 08 July 2020. The Indian market is up 7.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 13% over the same period.
お知らせ • Sep 26Link Pharma Chem Limited Appoints Rishikesh Thakur as Managing DirectorLink Pharma Chem Limited announced that Mr. Rishikesh Thakur has been appointed as Managing Director of the Company for period of three years with effect from September 24, 2020.
